Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118518) titled 'Clinical translational research on the integration of diagnosis and treatment of Her2-positive breast cancer with dual-mode radionuclide/fluorescence drugs' on Feb. 6.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of Dalian Medical University
Condition:
Her2-positive breast cancer.
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-03-01
Target Sample Size: HER2-Positive Cohort:20;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=298489
Disclaimer: Curated by HT Synd...